Literature DB >> 24388782

Remission induced by infliximab in a childhood polyarteritis nodosa refractory to conventional immunosuppression and rituximab.

Raquel Campanilho-Marques1, Filipa Ramos2, Helena Canhão3, João Eurico Fonseca3.   

Abstract

Entities:  

Keywords:  Infliximab; Juvenile cutaneous polyarteritis nodosa; Juvenile polyarteritis nodosa; Remission; Rituximab

Mesh：

Substances：

Year:  2013        PMID： 24388782     DOI： 10.1016/j.jbspin.2013.11.009

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  5 in total

Review 1.  Infliximab for the treatment of refractory polyarteritis nodosa.

Authors:  Shira Ginsberg; Itzhak Rosner; Gleb Slobodin; Michael Rozenbaum; Lisa Kaly; Nizar Jiries; Nina Boulman; Abid Awisat; Haya Hussein; Irina Novofastovski; Amal Silawy; Doron Rimar
Journal:  Clin Rheumatol       Date:  2019-04-10       Impact factor: 2.980

Review 2.  Unmet Needs in the Pathogenesis and Treatment of Vasculitides.

Authors:  Francesco Muratore; Giulia Pazzola; Alessandra Soriano; Nicolò Pipitone; Stefania Croci; Martina Bonacini; Luigi Boiardi; Carlo Salvarani
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 3.  A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report.

Authors:  Margaux Boistault; Mireia Lopez Corbeto; Ariadna Carsi Durall; Florence A Aeschlimann; Pierre Quartier; Laura Berbel Arcobé
Journal:  Pediatr Rheumatol Online J       Date:  2021-12-03       Impact factor: 3.054

Review 4.  Off-Label Uses of Rituximab in Dermatology.

Authors:  Connor Cole; Kyle T Amber
Journal:  Curr Dermatol Rep       Date:  2022-10-06

5.  The Successful Treatment of Refractory Polyarteritis Nodosa Using Infliximab.

Authors:  Satoko Matsuo; Keigo Hayashi; Eisaku Morimoto; Ayako Kato; Ken-Ei Sada; Haruki Watanabe; Mariko Takano-Narazaki; Katsue Sunahori-Watanabe; Tomoko Kawabata; Jun Wada
Journal:  Intern Med       Date:  2017-06-01       Impact factor: 1.271
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.